Compare Stocks: CMPX, PHAR, NVCT, and OLMA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$0.88 +2.6%	$1.82	$0.82 ▼ $6.88	$154.34M	1.02	7.37 million shs	4.97 million shs
NVCT Nuvectis Pharma	$18.00 -0.8%	$21.73	$5.55 ▼ $29.27	$592.49M	-0.24	213,931 shs	184,197 shs
OLMA Olema Pharmaceuticals	$6.80 -3.1%	$9.81	$6.61 ▼ $36.26	$614.23M	2	1.31 million shs	1.85 million shs
PHAR Pharming Group	$9.64 +2.1%	$10.91	$9.32 ▼ $21.34	$668.15M	-0.05	33,740 shs	3,949 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	+2.57%	-13.82%	-55.15%	-58.14%	-79.75%
NVCT Nuvectis Pharma	-0.83%	-11.29%	-22.91%	-3.23%	+198.51%
OLMA Olema Pharmaceuticals	-3.13%	-14.36%	-33.92%	-38.57%	-36.69%
PHAR Pharming Group	+2.12%	-0.10%	-10.91%	-27.46%	-33.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$0.88 +2.6%	$1.82	$0.82 ▼ $6.88	$154.34M	1.02	7.37 million shs	4.97 million shs
NVCT Nuvectis Pharma	$18.00 -0.8%	$21.73	$5.55 ▼ $29.27	$592.49M	-0.24	213,931 shs	184,197 shs
OLMA Olema Pharmaceuticals	$6.80 -3.1%	$9.81	$6.61 ▼ $36.26	$614.23M	2	1.31 million shs	1.85 million shs
PHAR Pharming Group	$9.64 +2.1%	$10.91	$9.32 ▼ $21.34	$668.15M	-0.05	33,740 shs	3,949 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	+2.57%	-13.82%	-55.15%	-58.14%	-79.75%
NVCT Nuvectis Pharma	-0.83%	-11.29%	-22.91%	-3.23%	+198.51%
OLMA Olema Pharmaceuticals	-3.13%	-14.36%	-33.92%	-38.57%	-36.69%
PHAR Pharming Group	+2.12%	-0.10%	-10.91%	-27.46%	-33.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	2.76	Moderate Buy	$10.25	1,066.10% Upside
NVCT Nuvectis Pharma	2.80	Moderate Buy	$36.25	101.39% Upside
OLMA Olema Pharmaceuticals	2.77	Moderate Buy	$40.60	497.06% Upside
PHAR Pharming Group	2.20	Hold	$38.67	301.11% Upside

Current Analyst Ratings Breakdown

Latest CMPX, PHAR, NVCT, and OLMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$39.00
9/23/2026	CMPX Compass Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/23/2026	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$4.00
9/23/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$38.00
9/23/2026	CMPX Compass Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$4.00
9/23/2026	CMPX Compass Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/23/2026	CMPX Compass Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Market Outperform	$4.00
9/22/2026	CMPX Compass Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Neutral	$5.00 ➝ $1.00
9/22/2026	CMPX Compass Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
9/22/2026	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$37.00
9/21/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	186.23	N/A	N/A	$1.11 per share	0.79
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.88 per share	N/A
PHAR Pharming Group	$376.13M	1.81	$0.20 per share	47.07	$3.95 per share	2.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$66.49M	-$0.40	N/A	N/A	N/A	N/A	-38.71%	-34.72%	11/4/2026 (Estimated)
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	11/9/2026 (Estimated)
PHAR Pharming Group	$2.85M	$0.12	80.33	35.70	N/A	2.51%	3.40%	1.90%	11/5/2026 (Estimated)

Latest CMPX, PHAR, NVCT, and OLMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	OLMA Olema Pharmaceuticals	-$0.60	N/A	N/A	N/A	$1.25 million	N/A
11/5/2026	Q3 2026	PHAR Pharming Group	$0.12	N/A	N/A	N/A	$103.54 million	N/A
11/4/2026	Q3 2026	CMPX Compass Therapeutics	-$0.12	N/A	N/A	N/A	$0.23 million	N/A
11/3/2026	Q3 2026	NVCT Nuvectis Pharma	-$0.22	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	11.22	11.22
NVCT Nuvectis Pharma	N/A	1.68	1.68
OLMA Olema Pharmaceuticals	0.01	8.86	8.86
PHAR Pharming Group	0.34	3.01	2.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
NVCT Nuvectis Pharma	96.77%
OLMA Olema Pharmaceuticals	91.78%
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	18.70%
NVCT Nuvectis Pharma	28.55%
OLMA Olema Pharmaceuticals	12.56%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	39	180.09 million	146.41 million	Not Optionable
NVCT Nuvectis Pharma	13	32.64 million	23.32 million	Not Optionable
OLMA Olema Pharmaceuticals	150	87.50 million	76.51 million	Optionable
PHAR Pharming Group	407	70.78 million	69.31 million	Not Optionable

CMPX, PHAR, NVCT, and OLMA Headlines

Recent News About These Companies

Pharming Reports Positive Phase II Data For Leniolisib In Rare Genetic Immune Disorders

October 14 at 9:35 AM | rttnews.com

Pharming's Leniolisib Shows Promise Beyond APDS In Rare Genetic Immune Disorders

October 14 at 9:35 AM | rttnews.com

Pharming Reports Positive Phase 2 Data for Leniolisib in Genetic Immune Disorders

October 14 at 9:35 AM | marketscreener.comM

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

October 14 at 2:00 AM | globenewswire.com

Pharming Group (NASDAQ:PHAR) Reaches New 52-Week Low - Should You Sell?

October 13 at 1:39 PM | marketbeat.com

Pharming Group (NASDAQ:PHAR) Reaches New 12-Month Low - Here's Why

October 7, 2026 | marketbeat.com

HC Wainwright Raises Earnings Estimates for Pharming Group

October 2, 2026 | marketbeat.com

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Stock Rated "Hold" by Wall Street Analysts

October 2, 2026 | marketbeat.com

Analysts Issue Forecasts for Pharming Group Q3 Earnings

October 1, 2026 | marketbeat.com

Pharming: Chief Executive Officer Fabrice Chouraqui Steps Down with Immediate Effect

September 30, 2026 | ideal-investisseur.frI

Pharming Appoints Leverne Marsh, Kenneth Lynard as Co-CEOs

September 29, 2026 | finance.yahoo.com

Pharmaceutical Executive Daily: Fabrice Chouraqui Steps Down as CEO of Pharming

September 29, 2026 | pharmexec.comP

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Here's What Happened

September 29, 2026 | marketbeat.com

Pharming Group N.V.: Pharming announces CEO transition

September 29, 2026 | finanznachrichten.de

Pharming CEO Fabrice Chouraqui Steps Down, Names Leverne Marsh, Kenneth Lynard Interim Co-CEOs

September 29, 2026 | rttnews.com

Pharming CEO Fabrice Chouraqui Resigns After Disagreement on Direction

September 29, 2026 | marketwatch.com

Pharming announces CEO transition

September 29, 2026 | globenewswire.com

FDA Accepts Pharming's SNDA For Lower-Dose Joenja In Children With APDS

September 26, 2026 | rttnews.com

Pharming Group N.V. Announces U.S. FDA Acceptance And Priority Review Of sNDA For Lower Doses Of Joenja To Treat Children With APDS

September 25, 2026 | marketscreener.comM

Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Time to Buy?

September 25, 2026 | marketbeat.com

Pharming Says FDA Accepts sNDA for Lower-Dose Joenja in Children With APDS

September 25, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CMPX, PHAR, NVCT, and OLMA Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$0.88 +0.02 (+2.57%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$0.86 -0.02 (-1.93%)

As of 04:51 AM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Nuvectis Pharma NASDAQ:NVCT

$18.00 -0.15 (-0.83%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$18.00 0.00 (-0.01%)

As of 04:52 AM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Olema Pharmaceuticals NASDAQ:OLMA

$6.80 -0.22 (-3.13%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$6.85 +0.05 (+0.74%)

As of 04:52 AM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Pharming Group NASDAQ:PHAR

$9.64 +0.20 (+2.12%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$9.64 -0.01 (-0.05%)

As of 10/14/2026 07:32 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMPX, PHAR, NVCT, and OLMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMPX, PHAR, NVCT, and OLMA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMPX, PHAR, NVCT, and OLMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CMPX, PHAR, NVCT, and OLMA Company Descriptions

Compass Therapeutics NASDAQ:CMPX

Nuvectis Pharma NASDAQ:NVCT

Olema Pharmaceuticals NASDAQ:OLMA

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMPX, PHAR, NVCT, and OLMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMPX, PHAR, NVCT, and OLMA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMPX, PHAR, NVCT, and OLMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CMPX, PHAR, NVCT, and OLMA Company Descriptions

Compass Therapeutics NASDAQ:CMPX

Nuvectis Pharma NASDAQ:NVCT

Olema Pharmaceuticals NASDAQ:OLMA

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools